Categories: Corporate and commercial, Intellectual Property, Life Sciences, Pharma, Biotech, Deals & Cases
VISCHER advised Proteomedix AG, a Swiss biotech subsidiary of Onconetix, Inc., on a licensing agreement with Immunovia AB, a Swedish pancreatic cancer diagnostics company. Under the agreement, Proteomedix will provide Immunovia with master cell lines for three of the five biomarkers in the PancreaSure test and will license its key manufacturing intellectual property to enable the company to produce the corresponding reagents. In return, Immunovia will pay USD 700,000 in 2025 and 2026 and a 3% royalty on net sales of PancreaSure and related products from 2026 through 2032. The transaction supports expanded access to innovative cancer diagnostics and earlier detection of pancreatic cancer, highlighting Proteomedix’s role in advancing early cancer detection.
The VISCHER team consisted of Christian Wyss (Partner, Corporate/M&A) and Rahel Widmer (Associate, Corporate/M&A).
Author: Christian Wyss
